BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15701432)

  • 1. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction.
    Delgado DH; Miriuka SG; Cusimano RJ; Feindel C; Rao V; Ross HJ
    J Heart Lung Transplant; 2005 Feb; 24(2):166-9. PubMed ID: 15701432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation.
    Rosenberg PB; Vriesendorp AE; Drazner MH; Dries DL; Kaiser PA; Hynan LS; Dimaio JM; Meyer D; Ring WS; Yancy CW
    J Heart Lung Transplant; 2005 Sep; 24(9):1327-31. PubMed ID: 16143252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
    J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
    Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
    J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients.
    Cibrik D; Meier-Kriesche HU; Bresnahan B; Wu YM; Klintmalm G; Kew CE; Kuo PC; Whelchel J; Cohen D; Baliga P; Akalin E; Benedetti E; Wright F; Lieberman B; Ulbricht B; Jensik S;
    Clin Transplant; 2007; 21(2):192-201. PubMed ID: 17425744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basiliximab and heart transplantation in Hispanics: the experience in Puerto Rico.
    Banchs HL; Carro Jiménez EJ; González V; González Cancel IF; Quintana C; Calderón R; Altieri PI; Rivera C
    Bol Asoc Med P R; 2007; 99(3):191-6. PubMed ID: 19610574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.
    Knight RJ; Kerman RH; Schoenberg L; Podder H; Van Buren CT; Katz S; Kahan BD
    Transplantation; 2004 Sep; 78(6):904-10. PubMed ID: 15385812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety.
    Kyllönen LE; Eklund BH; Pesonen EJ; Salmela KT
    Transplantation; 2007 Jul; 84(1):75-82. PubMed ID: 17627241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
    Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD
    Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction immunosuppression with basiliximab in heart transplantation.
    Chou NK; Wang SS; Chen YS; Yu HY; Chi NH; Wang CH; Ko WJ; Tsao CI; Sun CD
    Transplant Proc; 2008 Oct; 40(8):2623-5. PubMed ID: 18929820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation.
    Lin CC; Chuang FR; Lee CH; Wang CC; Chen YS; Liu YW; Jawan B; Chen CL
    Liver Transpl; 2005 Oct; 11(10):1258-64. PubMed ID: 16184544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients?
    Benavides C; Mahmoud KH; Knight R; Barcenas C; Kahan BD; Van Buren CT
    Transplant Proc; 2005 Mar; 37(2):822-6. PubMed ID: 15848544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial data on basiliximab in critically ill children undergoing heart transplantation.
    Ford KA; Cale CM; Rees PG; Elliott MJ; Burch M
    J Heart Lung Transplant; 2005 Sep; 24(9):1284-8. PubMed ID: 16143246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D; Kotnik V; Kandus A
    Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.